B
Beata Berent-Maoz
Researcher at University of California, Los Angeles
Publications - 37
Citations - 7409
Beata Berent-Maoz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 18, co-authored 34 publications receiving 5337 citations. Previous affiliations of Beata Berent-Maoz include Hebrew University of Jerusalem & Institute for Systems Biology.
Papers
More filters
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
Causes, consequences, and reversal of immune system aging
TL;DR: The effects of aging on the immune system are manifest at multiple levels that include reduced production of B and T cells in bone marrow and thymus and diminished function of mature lymphocytes in secondary lymphoid tissues, and elderly individuals do not respond to immune challenge as robustly as the young.
Journal ArticleDOI
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells,Marit M. van Buuren,Kristen K. Dang,Vanessa M. Hubbard-Lucey,Kathleen C. F. Sheehan,Katie M. Campbell,Andrew Lamb,Jeffrey P. Ward,John Sidney,Ana Belen Blazquez,Andrew J. Rech,Jesse M. Zaretsky,Begonya Comin-Anduix,Alphonsus H. C. Ng,William Chour,Thomas Yu,Hira Rizvi,Jia M. Chen,Patrice Manning,Gabriela Steiner,Xengie Doan,Aly A. Khan,Amit A. Lugade,Ana M. Mijalkovic Lazic,Angela Frentzen,Arbel D. Tadmor,Ariella Sasson,Arjun A. Rao,Baikang Pei,Barbara Schrörs,Beata Berent-Maoz,Beatriz M. Carreno,Bin Song,Bjoern Peters,Bo Li,Brandon W. Higgs,Brian Stevenson,Christian Iseli,Christopher A. Miller,Christopher A. Morehouse,Cornelis J. M. Melief,Cristina Puig-Saus,Daphne van Beek,David Balli,David Gfeller,David Haussler,Dirk Jäger,Eduardo Cortes,Ekaterina Esaulova,Elham Sherafat,Francisco Arcila,Gabor Bartha,Geng Liu,George Coukos,Guilhem Richard,Han Chang,Han Si,Inka Zörnig,Ioannis Xenarios,Ion I. Mandoiu,Irsan Kooi,James P. Conway,Jan H. Kessler,Jason A. Greenbaum,Jason Perera,Jason Harris,Jasreet Hundal,Jennifer M. Shelton,Jianmin Wang,Jiaqian Wang,Joel Greshock,Jonathon Blake,Joseph D. Szustakowski,Julia Kodysh,Juliet Forman,Lei Wei,Leo J. Lee,Lorenzo F. Fanchi,Maarten Slagter,Maren Lang,Markus Mueller,Martin Löwer,Mathias Vormehr,Maxim N. Artyomov,Michael A. Kuziora,Michael F. Princiotta,Michal Bassani-Sternberg,Mignonette H. Macabali,Milica R. Kojicic,Naibo Yang,Nevena M. Ilic Raicevic,Nicolas Guex,Nicolas Robine,Niels Halama,Nikola M. Skundric,Ognjen Milicevic,Pascal Gellert,Patrick Jongeneel,Pornpimol Charoentong,Pramod K. Srivastava,Prateek Tanden,Priyanka Shah,Qiang Hu,Ravi Gupta,Richard Chen,Robert A. Petit,Robert Ziman,Rolf Hilker,Sachet A. Shukla,Sahar Al Seesi,Sean Michael Boyle,Si Qiu,Siranush Sarkizova,Sofie R. Salama,Song Liu,Song Wu,Sriram Sridhar,Steven L. C. Ketelaars,Suchit Jhunjhunwala,Tatiana Shcheglova,Thierry Schuepbach,Todd Creasy,Veliborka Josipovic,Vladimir B. Kovacevic,Weixuan Fu,Willem-Jan Krebber,Yi-Hsiang Hsu,Yinong Sebastian,Zeynep Kosaloglu Yalcin,Zhiqin Huang,Taha Merghoub,Taha Merghoub,Justin Guinney,Justin Guinney,Adam Kolom,Cheryl Selinsky,Antoni Ribas,Antoni Ribas,Matthew D. Hellmann,Nir Hacohen,Nir Hacohen,Alessandro Sette,Alessandro Sette,James R. Heath,Nina Bhardwaj,Fred Ramsdell,Robert D. Schreiber,Ton N. Schumacher,Pia Kvistborg,Nadine Defranoux +149 more
TL;DR: A model of tumor epitope immunogenicity was developed that filtered out 98% of non-immunogenic peptides with a precision above 0.70 and was validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding.